Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease
Primary Purpose
Bowel Diseases, Inflammatory, Crohn Disease, Colitis, Ulcerative
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
BMGIM Music Therapy Method
Sponsored by
About this trial
This is an interventional supportive care trial for Bowel Diseases, Inflammatory focused on measuring Music Therapy
Eligibility Criteria
Inclusion Criteria:
- Over 18 years old,
- Diagnosed IBD (EC or UC) in the remission phase,
- They did not receive treatment with corticosteroids at least in the two months prior to the start of the study,
- They did not receive any extra pharmacological treatment,
- Attend the collaborating hospital center with the study, in this case, the University General Hospital of Valencia,
- Attend the schedule and schedule established for the study,
- Accept the conditions of participation in the study indicated in the signed informed consent prior to the start of the study
- * Do not take corticosteroids during the 8 weeks between the pre-test and the post-test,
- * Perform the pre-test before starting session 1 (in case of experimental group) or appointment 1 (in case of control group); and then the retest at the end of session 8 (in the case of an experimental group) or appointment with nursing after 8 weeks (in the case of a control group).
- * In the case of the patients belonging to the experimental group, who at the end of the 8 weeks of treatment would have attended at least 6 of the 8 sessions established (and that, obligatorily, 2 of them were 1 and 8, where the shots were taken) sample and completed the questionnaires).
Exclusion Criteria:
The patients who were excluded from this study were those who did not meet the requirements indicated in the inclusion criteria, or who showed aversion or rejection to this type of therapy.
Sites / Locations
- Universitat de València
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Control Group
Experimental Group
Arm Description
Outcomes
Primary Outcome Measures
Change in biological markers in saliva samples using enzyme-linked immunosorbent biological markers assay (ELISA) (PRE and POST Measures).
Quantifying change in biological markers in saliva samples using enzyme-linked immunosorbent assay (ELISA). (IgA level & Salivary Cortisol) comparing pre and post intervention
Change in biological markers in hair using enzyme-linked immunosorbent assay (ELISA).(PRE and POST Measures).
Quantifying change in biological markers in hair (Cortisol Hair) comparing pre and post intervention
Change in Hospital Anxiety and Depression Scale (HADS) (PRE and POST Measures)
14 items. 7 items for Anxiety and 7 for Depression. The score for the items is evaluated on a Likert scale ranging from 0 to 3 points, where 0 represents never or almost never, 1 a little or from time to time, 2 somewhat less than before or not as intense, and 3 maximum or almost always. Lastly, it is worth mentioning that these scales are interpreted based on the sum of each dimension, with 21 as the maximum, both for depression and for anxiety. Higher values represent a worse outcome. Observing change comparing pre and post intervention
Change in Short-form Questionnaire on Quality of Life in IBD (CCVEII-9) (PRE and POST Measures)
9 items grouped in a single dimension The final score is expressed on a scale of 0 to 100 points, such that a lower score corresponds to a lower quality of life and vice versa. Observing change comparing pre and post intervention
Change in the MOOD questionnaire (PRE and POST Measures).
The scale evaluates the frequency of the different states of mind (happiness, anger, sadness, and fear) based on 20 items (4 dimensions of 5 items each). The responses for the items were measured using a 3-point Likert scale (1=never, 2=sometimes, 3=often). Each dimension range from 1 to 3. There is not a total of all dimensions together. a lower score corresponds to high level fo that mood (lower values= a betwer outcome on anger, sadness, and fear and worst outcome on hapiness). Observing change comparing pre and post intervention
Secondary Outcome Measures
Full Information
NCT ID
NCT03999294
First Posted
June 5, 2019
Last Updated
June 25, 2019
Sponsor
University of Valencia
Collaborators
Universidad Católica de Valencia San Vicente Mártir, Hospital General Universitario de Valencia
1. Study Identification
Unique Protocol Identification Number
NCT03999294
Brief Title
Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease
Official Title
The Influence of the Bmgim Music Therapy Method in the Reduction of Stress in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis): Quantitative and Qualitative Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
April 1, 2015 (Actual)
Primary Completion Date
June 30, 2016 (Actual)
Study Completion Date
January 31, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Valencia
Collaborators
Universidad Católica de Valencia San Vicente Mártir, Hospital General Universitario de Valencia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Inflammatory bowel disease (IBD) is a term that defines a chronic disease characterized by inflammation of the intestine. It includes ulcerative colitis (UC) and Crohn's disease (CD). The objective of the study was to administer a treatment based on a group adaptation of the BMGIM in patients with inflammatory bowel disease (IBD) and assess its impact on state of mind, quality of life, anxiety, depression, immunocompetence as a marker of well-being, and levels of acute and chronic stress.
To achieve the objectives a quasi-experimental, quantitative, qualitative, analytical, and prospective study was performed. 41 patients with IBD divided into a test group (24 patients), who received 8 sessions over 8 weeks, and a control group (17 patients). A saliva sample was taken from each patient before and after each session to determine cortisol levels (acute stress) and IgA (immunocompetence) using ELISA. A series of questionnaires were completed as follows: HADS (perceived anxiety), MOOD (state of mind), and CCVEII (quality of life). Similarly, a hair sample was taken before the first and after the last session to determine the cumulative cortisol level (chronic stress) using ELISA.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bowel Diseases, Inflammatory, Crohn Disease, Colitis, Ulcerative
Keywords
Music Therapy
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
51 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control Group
Arm Type
No Intervention
Arm Title
Experimental Group
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
BMGIM Music Therapy Method
Intervention Description
The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
Primary Outcome Measure Information:
Title
Change in biological markers in saliva samples using enzyme-linked immunosorbent biological markers assay (ELISA) (PRE and POST Measures).
Description
Quantifying change in biological markers in saliva samples using enzyme-linked immunosorbent assay (ELISA). (IgA level & Salivary Cortisol) comparing pre and post intervention
Time Frame
Baseline up to 8 weeks of treatment
Title
Change in biological markers in hair using enzyme-linked immunosorbent assay (ELISA).(PRE and POST Measures).
Description
Quantifying change in biological markers in hair (Cortisol Hair) comparing pre and post intervention
Time Frame
Baseline up to 8 weeks of treatment
Title
Change in Hospital Anxiety and Depression Scale (HADS) (PRE and POST Measures)
Description
14 items. 7 items for Anxiety and 7 for Depression. The score for the items is evaluated on a Likert scale ranging from 0 to 3 points, where 0 represents never or almost never, 1 a little or from time to time, 2 somewhat less than before or not as intense, and 3 maximum or almost always. Lastly, it is worth mentioning that these scales are interpreted based on the sum of each dimension, with 21 as the maximum, both for depression and for anxiety. Higher values represent a worse outcome. Observing change comparing pre and post intervention
Time Frame
Baseline up to 8 weeks of treatment
Title
Change in Short-form Questionnaire on Quality of Life in IBD (CCVEII-9) (PRE and POST Measures)
Description
9 items grouped in a single dimension The final score is expressed on a scale of 0 to 100 points, such that a lower score corresponds to a lower quality of life and vice versa. Observing change comparing pre and post intervention
Time Frame
Baseline up to 8 weeks of treatment
Title
Change in the MOOD questionnaire (PRE and POST Measures).
Description
The scale evaluates the frequency of the different states of mind (happiness, anger, sadness, and fear) based on 20 items (4 dimensions of 5 items each). The responses for the items were measured using a 3-point Likert scale (1=never, 2=sometimes, 3=often). Each dimension range from 1 to 3. There is not a total of all dimensions together. a lower score corresponds to high level fo that mood (lower values= a betwer outcome on anger, sadness, and fear and worst outcome on hapiness). Observing change comparing pre and post intervention
Time Frame
Baseline up to 8 weeks of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Over 18 years old,
Diagnosed IBD (EC or UC) in the remission phase,
They did not receive treatment with corticosteroids at least in the two months prior to the start of the study,
They did not receive any extra pharmacological treatment,
Attend the collaborating hospital center with the study, in this case, the University General Hospital of Valencia,
Attend the schedule and schedule established for the study,
Accept the conditions of participation in the study indicated in the signed informed consent prior to the start of the study
* Do not take corticosteroids during the 8 weeks between the pre-test and the post-test,
* Perform the pre-test before starting session 1 (in case of experimental group) or appointment 1 (in case of control group); and then the retest at the end of session 8 (in the case of an experimental group) or appointment with nursing after 8 weeks (in the case of a control group).
* In the case of the patients belonging to the experimental group, who at the end of the 8 weeks of treatment would have attended at least 6 of the 8 sessions established (and that, obligatorily, 2 of them were 1 and 8, where the shots were taken) sample and completed the questionnaires).
Exclusion Criteria:
The patients who were excluded from this study were those who did not meet the requirements indicated in the inclusion criteria, or who showed aversion or rejection to this type of therapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vicente Javier Prado Gascó
Organizational Affiliation
Universitat de València
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitat de València
City
Valencia
ZIP/Postal Code
46010
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease
We'll reach out to this number within 24 hrs